FAP and neoplasm: In a 2014 study, the FAP-activated prodrug ERGETGP-S12ADT effectively suppressed tumor growth in mouse xenograft models of human breast and prostate cancers with efficacy comparable to docetaxel but markedly lower systemic toxicity [191].